帮忙翻译一下
本回答由提问者推荐
var sogou_ad_id=731547;
var sogou_ad_height=160;
var sogou_ad_width=690;帮忙翻译一下句子。
在沪江关注日语的沪友jhjuly遇到了一个关于新能力考N1的疑惑，已有2人提出了自己的看法。
知识点疑惑描述：
帮忙解释一下括号里的词在句中是什么意思，以及整句话是什么意思。
IV（7）IVこれまでお研究に(もとづいて)レポートをまとめた。
IV（8）頼み方(次第では)あの人もこの仕事を手伝ってくれるかもしれない。
V（6）先月バイオリンこコンタールで一位になったからお祝いの手紙をたくさんもらったが、忙しくて返事が　(書ききれない)。
VI（2）山本さんが難しい試験に合格した。ご両親(をはじめ)、先生がたも喜んでいらっしゃる。
最佳知识点讲解
知识点相关讲解
帮忙解释一下括号里的词在句中是什么意思，以及整句话是什么意思。
IV（7）IVこれまでお研究に(もとづいて)レポートをまとめた。
「名词+にもどづいて」按照...;根据…还可以有「にもどづいた+名词」「にもどづいての+名词」的形式.
根据你以前的研究,归纳写成了论文.
IV（8）頼み方(次第では)あの人もこの仕事を手伝ってくれるかもしれない。
「名词+次第では」根据. 表示根据”名词”的情况而定的意思.
看委托方的情况,也许他会帮我们做这个工作.
V（6）先月バイオリンのコンクールで一位になったからお祝いの手紙をたくさんもらったが、忙しくて返事が　(書ききれない)。
「动词连用形+きれない」不能完全.
因为在上个月的小提琴比赛中得了冠军,祝贺的信件象雪片似的飞来,忙得我回信写也写不完.
VI（2）山本さんが難しい試験に合格した。ご両親(をはじめ)、先生がたも喜んでいらっしゃる。
「名词+をはじめ（として）」以…为首,以及.
山田在很难的考试中及格了.父母亲以及老师们也都非常高兴.
—— xiebokang
もとづいて:基于
到此为止(目前)根据你的研究,整理的报告.
次第では:要看....
那个人也许会帮这件事就要看求的人(是谁)
書ききれない:写不完
上个月在小提琴演奏会上得了第一名以后,收到很多祝贺的信,因为很忙回信都写不完.
をはじめ:以...为首(例)
山本先生通过了很难的考试,以父母亲为首,老师也很高兴的要来
—— takatoka
相关其他知识点帮忙翻译一下这个句子，谢谢
在沪江关注考试英语的沪友WALDNERLING遇到了一个关于专四专八的疑惑，并悬赏20沪元，已有2人提出了自己的看法。
知识点疑惑描述：
Those of us who pushed for the bill will consider ourselves most successful if it acts as an incentive not to have it invoke in the first place.
push for the bill啥意思？if it acts as an incentive not to have it invoke这句怎么解释，其中两个it分别指什么？
最佳知识点讲解
知识点相关讲解
push for the bill
推动该法案
—— 尤美娜
这两个it都是指the bill（这个法案）
我们这些推动该法案的人可以说是最成功的如果这个法案能当做刺激和鼓励而不是诉诸
—— Chirena
相关其他知识点小木虫 --- 600万学术达人喜爱的学术科研平台
&&查看话题
帮忙翻译一下呢！
Lung Cancer Vaccine Enters Large-scale Clinical Trial
A new treatment for the most common form of lung cancer, developed from initial research by Cancer Research UK entists, has entered a pivotal phase III clinical trial.
The drug, called Stimuvax, is a type of therapeutic vaccine that targets a specific protein found in many tumours, including non-small cell lung cancer. It was developed by Canadian biotech company Biomira following Cancer Research UK-funded studies led by Professor Joyce Taylor-Papadimitriou of Guy's Hospital, London. Biomira have already run phase II trials with very encouraging results.
The international phase III trial, named START (Stimulating Targeted Antigenic Responses To NSCLC), is expected to enrol its first patient this month. Run by pharmaceutical company Merck KGaA, it will eventually include more than 1,300 lung cancer patients in 30 countries, including the UK.
Therapeutic vaccines are a relatively new development in cancer treatment. Unlike preventative vaccines, they are treatments that induce the body's own immune system to identify and kill existing cancer cells. Stimuvax is designed to stimulate the immune system to recognise and react to a molecule called MUC1, which is much more abundant on tumour cells than healthy cells. The immune system then kills the cancer cells with MUC1, hopefully without overly harming healthy cells.
Cancer Research Technology Limited (CRT), Cancer Research UK's development and commercialisation company, licensed a number of discoveries to Biomira, which led to the development of Stimuvax for advanced non small cell lung cancer. Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer.
Dr Keith Blundy, chief operating officer of CRT, said: "We are extremely pleased that Stimuvax has entered the final stage of clinical trials. The drug is one of CRT's portfolio of more than 20 partnered agents in clinical development. Targeted vaccines are an exciting approach that could potentially offer new treatment options for major types of cancer."
Harpal Kumar, chief executive of CRT and chief operating officer of Cancer Research UK, said: "We're delighted that another drug based on Cancer Research UK-funded basic research has reached the final stage of clinical development. The 'translation' of basic research into patient benefit is the major focus of our work and we hope that new ventures, such as the expansion of our drug discovery activities across the country, will lead to many more such drugs entering trials in the future."
Lung cancer
-- Lung cancer is the second most common cancer in the UK after breast cancer, and the most common cancer worldwide.
-- There were more than 37,000 cases of lung cancer diagnosed in the UK in 2003.
-- Non small cell lung cancer accounts for 80 per cent of total lung cancer cases.
-- Current standard treatments for lung cancer patients are surgery, platinum-based combination chemotherapy and radiotherapy.
START trial
In the trials, Stimuvax will be compared to a placebo. More information on the START trial can be found here.
Research centres in Edinburgh, Leeds and Exeter will be participating in the trial.
For more information about clinical trials in the UK, visit Cancer Research UK's patient information website, CancerHelp UK.
Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found here.
About Cancer Research UK
Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
-- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
-- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
-- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
-- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
2030人参与
关于帮忙翻译一下呢！的相关话题在小木虫APP已经有171位虫友给出了详细回复。
赶快查看回复吧！
学术必备与600万学术达人在线互动！
扫描下载送金币
北京学而思教育科技有限公司 地址：北京市海淀区北三环甲18号中鼎大厦A座1层102室 电话：010-
浏览器进程
打开微信扫一扫
随时随地聊科研